Another meta‐analysis of three RCTs of GLP‐1 therapies looking at AP as a predefined and independently adjudicated adverse event also found no elevated risk in T2D patients (Peto OR, 0.745 [95% CI, 0.47‐1.17]).39 This result is in contrast to that of two similar meta‐analyses of DPP‐4i RCT that found significant increases in AP risk in the treatment group vs controls. The gene discussed is GCG; the disease is type 2 diabetes mellitus.